Fierce Pharma

While BioMarin has been focusing heavily on its CNP analogue, [...]

Amgen’s Amjevita, Aimovig and Repatha—plus GSK’s Ellipta inhalers and its [...]

Idorsia is gearing up for another CEO change with the [...]

The CEO’s 2025 pay was a sizeable bump over the [...]

GSK has secured an FDA expansion for its respiratory syncytial [...]

From its 17-year development cycle through to its commercial launch, [...]

Simtra BioPharma Solutions was issued a warning letter by the [...]

The FDA has rejected Hyloris Pharmaceuticals’ antiviral valacyclovir, an oral [...]

Eli Lilly is making investments in China, Japan and South [...]

While much of the company’s recent focus has remained on [...]